Orchestra BioMed (OBIO) 10-Q/A 31 Mar 22 2021 Q3 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 12, 2021
Document Information Line Items
Entity Registrant Name	Health Sciences Acquisitions Corp 2
Trading Symbol	HSAQ
Document Type	10-Q/A
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,450,000
Amendment Flag	true
Amendment Description	This Amendment No. 1 (“Amendment No. 1”) to the Quarterly Report on Form 10-Q/A amends the Quarterly Report on Form 10-Q of Health Sciences Acquisition Corporation 2 (the “Company”) as of and for the period ended September 30, 2021, as filed with the Securities and Exchange Commission (“SEC”) on November 12, 2021 (the “Original Form 10-Q”).On November 12, 2021, the Company filed its Form 10-Q for the quarterly period ending September 30, 2021, which included a section within Note 2, Revision to Previously Reported Financial Statements, that described a revision to the Company’s classification of its ordinary shares subject to redemption issued as part of the units sold in the Company’s initial public offering (“Initial Public Offering”) on August 6, 2020 (the “Public Shares”). As described in Note 2, upon its Initial Public Offering, the Company classified a portion of the Public Shares as permanent equity to maintain net tangible assets greater than $5,000,000 on the basis that the Company will consummate its initial business combination only if the Company has net tangible assets of at least $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. The Company revised this interpretation to include temporary equity in net tangible assets. As a result, management corrected the error by reclassifying all Public Shares subject to redemption as temporary equity. This resulted in an adjustment to the initial carrying value of the Public Shares subject to possible redemption with the offset recorded to additional paid-in capital (to the extent available), accumulated deficit and ordinary shares.In connection with the change in presentation for the ordinary shares subject to possible redemption, the Company restated its earnings per share calculation to allocate income and losses to all of its ordinary shares instead of two-class method. This presentation contemplates a Business Combination as the most likely outcome. Previously, the Company determined the changes were not qualitatively material to the Company’s previously issued financial statements and did not restate its financial statements. Instead, the Company revised its previously reported financial statements in Note 2 to its Original Form 10-Q. Although the qualitative factors that management assessed tended to support a conclusion that the misstatements were not material, these factors were not strong enough to overcome the significant quantitative errors in the financial statements. The qualitative and quantitative factors support a conclusion that the misstatements are material on a quantitative basis. Management concluded that the misstatement was such of magnitude that it is probable that the judgment of a reasonable person relying upon the financial statements would have been influenced by the inclusion or correction of the foregoing items. As such, upon further consideration of the change, the Company determined the change in classification of the ordinary shares and change to its presentation of earnings per share is material quantitatively and it should restate its previously issued financial statements.Therefore, on February 4, 2021, the Company’s management and the audit committee of the Company’s board of directors (the “Audit Committee”) concluded that the Company’s previously issued (i) audited balance sheet as of August 6, 2020 included in the Company’s Current Report on Form 8-K filed with the SEC on August 12, 2020 (the “Post-IPO Balance Sheet”), (ii) unaudited condensed financial statements as of and for the quarterly period ended September 30, 2020 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, (iii) audited annual financial statements as of and for the period ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 10, 2021 (iv) unaudited condensed financial statements as of and for the quarterly period ended March 31, 2021 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 17, 2021, (v) unaudited condensed financial statements as of and for the quarterly period ended June 30, 2021 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 16, 2021, and (vi) a section within footnote 2 to unaudited condensed financial statements as of and for the quarterly period ended September 30, 2021, and Item 4 included, reported in the Original Form 10-Q as filed with the SEC, (collectively, the “Affected Periods”), should be restated to report all Public Shares as temporary equity and change the earnings per share presentation, and should no longer be relied upon.As such, the Company is restating in this Form 10-Q/A the unaudited condensed financial statements for the quarterly periods ended March 31, 2021, June 30, 2021, and September 30, 2021. The Post-IPO Balance Sheet, audited financial statements for the year ended December 31, 2020 and the unaudited condensed financial statements for the quarterly period ended September 30, 2020 were restated in the Amendment No. 1 to the Form 10-K/A for the period ended December 31, 2020.The restatement did not have any impact on its cash position or cash held in the trust account established in connection with the Initial Public Offering.After re-evaluation, the Company’s management has concluded that, in light of the errors described above, a material weakness existed in the Company’s internal control over financial reporting during the Affected Periods and that the Company’s disclosure controls and procedures were not effective. The Company’s remediation plan with respect to such material weakness is described in more detail in Item 4 of this filing.This Amendment No. 1 on Form 10-Q/A sets forth the Original Form 10-Q in its entirety, as amended to reflect the restatement. Among other things, forward-looking statements made in the Original Form 10-Q have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Form 10-Q, and such forward-looking statements should be read in their historical context.The following items have been amended as a result of the restatement:Part I, Item 1, Financial StatementsPart I, Item 4, Controls and ProceduresIn accordance with applicable SEC rules, this Amendment No. 1 on Form 10-Q/A includes an updated signature page and certifications of our Chief Executive Officer and Chief Financial Officer in Exhibits 31.1, 31.2 and 32.1 as required by Rule 12b-15.Refer to Note 2, Restatement of Previously Issued Financial Statements of this Form 10-Q/A for additional information and for the summary of the accounting impacts of these adjustments to the Company’s unaudited condensed financial statements as of and for the period ended March 31, 2021 and as of and for the period ended June 30, 2021.Except as described above, no other information included in Original Form 10-Q is being amended or updated by this Amendment No. 1 and, other than as described herein, this Amendment No. 1 does not purport to reflect any information or events subsequent to the Original Form 10-Q. We have not amended our previously filed Quarterly Reports on Form 10-Q for the periods affected by the restatement. This Amendment No. 1 continues to describe the conditions as of the date of the Original Form 10-Q and, except as expressly contained herein, we have not updated, modified or supplemented the disclosures contained in the Original Form 10-Q. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-Q and with our filings with the SEC subsequent to the Original Form 10-Q.
Entity Central Index Key	0001814114
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	true
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	E9
Entity File Number	001-39421
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	40 10th Avenue
Entity Address, Address Line Two	Floor 7
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10014
City Area Code	(646)
Local Phone Number	597-6980
Title of 12(b) Security	Ordinary Shares
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 1,783,295	$ 2,026,822
Prepaid expenses	81,167	122,478
Total current assets	1,864,462	2,149,300
Investments held in Trust Account	160,018,413	160,006,444
Total Assets	161,882,875	162,155,744
Current liabilities:
Accounts payable	1,655	13,810
Accrued expenses	15,174	75,146
Accrued expenses - related party	120,000	30,000
Total current liabilities	136,829	118,956
Deferred underwriting commissions in connection with the initial public offering	5,600,000	5,600,000
Total liabilities	5,736,829	5,718,956
Commitments and Contingencies
Ordinary shares subject to possible redemption, $0.0001 par value; 16,000,000 shares issued and outstanding at $10.00 per share redemption value as of September 30, 2021, and December 31, 2020	160,000,000	160,000,000
Shareholders’ Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of September 30, 2021 and December 31, 2020
Ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 4,450,000 non-redeemable shares issued and outstanding as of September 30, 2021, and December 31, 2020	445	445
Additional paid-in capital
Accumulated deficit	(3,854,399)	(3,563,657)
Total shareholders’ deficit	(3,853,954)	(3,563,212)
Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit	$ 161,882,875	$ 162,155,744

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares subject to possible redemption, shares issued	16,000,000	16,000,000
Ordinary shares subject to possible redemption, shares oustanding	16,000,000	16,000,000
Ordinary shares subject to possible redemption value per share (in Dollars per share)	$ 10	$ 10
Preference shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preference shares, shares authorized	1,000,000	1,000,000
Preference shares, shares issued
Preference shares, shares outstanding
Ordinary shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, shares issued	4,450,000	4,450,000
Ordinary shares, shares outstanding	4,450,000	4,450,000

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($)	3 Months Ended		4 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2021
Operating expenses
General and administrative expenses	$ 64,445	$ 68,625	$ 83,839	$ 212,711
Administrative fee - related party	30,000			90,000
Loss from operations	(94,445)	(68,625)	(83,839)	(302,711)
Interest income from investments held in Trust Account	4,034	2,411	2,411	11,969
Net loss	$ (90,411)	$ (66,214)	$ (81,428)	$ (290,742)
Weighted average shares outstanding of ordinary shares, basic and diluted (in Shares)	20,450,000	13,808,885	11,964,131	20,450,000
Basic and diluted net loss per share, ordinary shares (in Dollars per share)	$ 0	$ 0	$ (0.01)	$ (0.01)

Unaudited Condensed Statement_2

Unaudited Condensed Statements of Changes in Shareholders’ Deficit - USD ($)	Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at May. 24, 2020
Issuance of ordinary shares to Sponsor	$ 400	28,350		28,750
Issuance of ordinary shares to Sponsor (in Shares)	4,000,000
Net loss			(15,215)	(15,215)
Balance at Jun. 30, 2020	$ 400	28,350	(15,215)	13,535
Balance (in Shares) at Jun. 30, 2020	4,000,000
Sale of private placement shares and private placement warrants to Sponsor in a private placement	$ 45	5,999,955		6,000,000
Sale of private placement shares and private placement warrants to Sponsor in a private placement (in Shares)	450,000
Accretion on ordinary shares subject to possible redemption amount		(6,028,305)	(3,390,115)	(9,418,420)
Net loss			(66,214)	(66,214)
Balance at Sep. 30, 2020	$ 445		(3,471,544)	(3,471,099)
Balance (in Shares) at Sep. 30, 2020	4,450,000
Balance at Dec. 31, 2020	$ 445		(3,563,657)	(3,563,212)
Balance (in Shares) at Dec. 31, 2020	4,450,000
Net loss			(108,002)	(108,002)
Balance at Mar. 31, 2021	$ 445		(3,671,659)	(3,671,214)
Balance (in Shares) at Mar. 31, 2021	4,450,000
Net loss			(92,329)	(92,329)
Balance at Jun. 30, 2021	$ 445		(3,763,988)	(3,763,543)
Balance (in Shares) at Jun. 30, 2021	4,450,000
Net loss			(90,411)	(90,411)
Balance at Sep. 30, 2021	$ 445		$ (3,854,399)	$ (3,853,954)
Balance (in Shares) at Sep. 30, 2021	4,450,000

Unaudited Condensed Statement_3

Unaudited Condensed Statements of Cash Flows - USD ($)	4 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021
Cash Flows from Operating Activities:
Net loss	$ (81,428)	$ (290,742)
Adjustments to reconcile to net loss to net cash used in operating activities
Interest income from investments held in Trust Account	(2,411)	(11,969)
Changes in operating assets and liabilities:
Prepaid expenses	(160,127)	41,311
Accounts payable	1,445	(12,155)
Accrued expenses	(5,000)	(59,972)
Accrued expenses - related party		90,000
Net cash used in operating activities	(247,521)	(243,527)
Cash Flows from Investing Activities
Principal deposited in Trust Account	(160,000,000)
Net cash used in investing activities	(160,000,000)
Cash Flows from Financing Activities:
Proceeds from issuance of ordinary shares to Sponsor	28,750
Proceeds from note payable to related party	300,000
Repayment of note payable to related party	(300,000)
Proceeds received from initial public offering, gross	160,000,000
Proceeds from private placement	6,000,000
Paid offering costs	(3,743,420)
Net cash provided by financing activities	162,285,330
Net change in cash	2,037,809	(243,527)
Cash - beginning of the period		2,026,822
Cash - end of the period	2,037,809	1,783,295
Supplemental disclosure of noncash activities:
Offering costs included in accrued expenses	70,000
Deferred underwriting commissions in connection with the initial public offering	$ 5,600,000

Description of Organization and

Description of Organization and Business Operations	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Description of Organization and Business Operations	Note 1 - Description of Organization and Business Operations Health Sciences Acquisitions Corporation 2 (the “Company”) was incorporated on May 25, 2020, in the Cayman Islands as a business company with limited liability and formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, contractual control arrangement with, purchasing all or substantially all of the assets of, or engaging in any other similar initial business combination with one or more businesses or entities (“Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on healthcare innovation. The Company has neither engaged in any operations nor generated revenue to date. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”). As of September 30, 2021, the Company had not commenced any operations. All activity for the period from May 25, 2020 (inception) through September 30, 2021, had been related to the Company’s formation and the initial public offering (“Initial Public Offering”), and since the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenue until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income from its investments held in the Trust Account (as defined below). The Company’s sponsor is HSAC 2 Holdings, LLC (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on August 3, 2020. On August 6, 2020, the Company consummated its Initial Public Offering of 16,000,000 ordinary shares (the “Public Shares”), including the issuance of 2,086,956 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $160.0 million, and incurring offering costs of approximately $9.4 million, inclusive of approximately $5.6 million in deferred underwriting commissions (Note 7). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share to the Sponsor, (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (“Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (Note 5). Upon the closing of the Initial Public Offering and the Private Placement, $160.0 million ($10.00 per Public Share) of the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a U.S based trust account (“Trust Account”), maintained by Continental Stock Transfer & Trust Company, acting as trustee, and invested in U.S. “government securities” with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act of 1940 (the “Investment Company Act”), which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. Pursuant to stock exchange listing rules, the Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of any deferred underwriting discount held in trust and taxes payable on the income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Shares and Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully complete a Business Combination. The Company will provide holders of the Public Shares (“Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per ordinary share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). As a result, such ordinary shares have been recorded at redemption amount and classified as temporary equity, in accordance with the Financial Accounting Standard Board (“FASB”), Accounting Standard Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account is initially anticipated to be $10.00 per Public Share. In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the ordinary shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which will be adopted by the Company upon the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem ordinary shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Insider Shares prior to this Initial Public Offering (the “Initial Shareholders”) have agreed to vote their Insider Shares (as defined in Note 6) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their Insider Shares, Private Placement Shares, and Public Shares in connection with the completion of a Business Combination. In addition, the Company has agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its ordinary shares with respect to more than an aggregate of 20% or more of the ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, executive officers, directors and director nominees have agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment. If a Business Combination has not been consummated by August 6, 2022 (the “Combination Period”), it will trigger the Company’s automatic winding up, liquidation and dissolution. If the Company does not consummate a Business Combination within the Combination Period, upon notice from the Company, the trustee of the Trust Account will distribute the amount in the Trust Account to the Public Shareholders. Concurrently, the Company shall pay, or reserve for payment, from funds not held in the Trust Account, its liabilities and obligations, although the Company cannot assure that there will be sufficient funds for such purpose. If there are insufficient funds held outside the Trust Account for such purpose, the Sponsor has agreed that it will be liable to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company and which have not executed a waiver agreement. However, the Company cannot assure that the liquidator will not determine that he or she requires additional time to evaluate creditors’ claims (particularly if there is uncertainty over the validity or extent of the claims of any creditors). The Company also cannot assure that a creditor or shareholder will not file a petition with the Cayman Islands Court which, if successful, may result in the Company’s liquidation being subject to the supervision of that court. Such events might delay distribution of some or all of the Company’s assets to the Public Shareholders. The Initial Shareholders have agreed to waive their liquidation rights with respect to the Insider Shares and Private Placement Shares (collectively, “Founder Shares”) held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 7) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per ordinary share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per ordinary share initially held in the Trust Account. Liquidity and Going Concern The accompanying unaudited condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of September 30, 2021, the Company had approximately $1.8 million in its operating bank account and working capital of approximately $1.7 million. Prior to the completion of the Initial Public Offering, the Company’s liquidity needs had been satisfied through the capital contribution of $28,750 from the Sponsor to purchase the Insider Shares, and a loan of $300,000 pursuant to the Note issued to the Sponsor, which was repaid on August 7, 2020 (Note 6). Subsequent to the consummation of the Initial Public Offering and Private Placement, the Company’s liquidity needs have been satisfied with the proceeds from the consummation of the Private Placement not held in the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor may, but is not obligated to, provide the Company Working Capital Loans (see Note 6). As of September 30, 2021, and December 31, 2020, there were no amounts outstanding under any Working Capital Loans. Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. However, in connection with the Company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after August 6, 2022.

Restatement of Previously Repor

Restatement of Previously Reported Financial Statements	9 Months Ended
	Sep. 30, 2021
Restatement Of Previously Reported Financial Statements [Abstract]
Restatement of Previously Reported Financial Statements	Note 2 - Restatement of Previously Reported Financial Statements In the Company’s unaudited condensed financial statements as of and for quarterly period ended September 30, 2021, as filed with the SEC on November 12, 2021, the Company concluded it should restate its previously reported financial statements to classify all Public Shares subject to possible redemption in temporary equity. In accordance, ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company had previously classified a portion of its Public Shares in permanent equity, or total shareholders’ equity. Although the Company did not specify a maximum redemption threshold, its charter currently provides that, the Company will not redeem its public shares in an amount that would cause its net tangible assets to be less than $5,000,001. Previously the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. The Company revised this interpretation to include temporary equity in net intangible assets. In connection with the change in presentation for the ordinary shares subject to possible redemption, the Company restated its earnings per share calculation to allocate income and losses to its ordinary shares instead of two-class method. This presentation contemplates a Business Combination as the most likely outcome. In accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” and SEC Staff Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company evaluated the corrections and has determined that the related impact was material to the previously filed financial statements that contained the error, reported in the Company’s Form 10-Qs for the quarterly periods ended March 31, 2021, and June 30, 2021 (the “Affected Quarterly Periods”). Therefore, the Company, in consultation with its Audit Committee, concluded that the Affected Quarterly Periods should be restated to present all Public Shares subject to possible redemption as temporary equity, to recognize accretion from the initial book value to redemption value at the time of its Initial Public Offering and change in earnings per share. As such, the Company is reporting these restatements to the Affected Quarterly Periods in this quarterly report. The previously presented Affected Quarterly Periods should no longer be relied upon. The impact of the restatement on the financial statements for the Affected Quarterly Periods is presented below. There is no impact to the reported amounts for total assets, total liabilities, cash position, and net income (loss). The tables below present the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported unaudited condensed balance sheet as of March 31, 2021, statement of operations and statement of cash flows for the quarter ended March 31, 2021: As of March 31, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Balance Sheet Total Assets $ 162,103,252 $ - $ 162,103,252 Total liabilities $ 5,774,466 $ - $ 5,774,466 Ordinary shares subject to possible redemption 151,328,780 8,671,220 160,000,000 Shareholders’ equity (deficit) Preference shares - - - Ordinary shares 532 (87 ) 445 Additional paid-in-capital 5,281,018 (5,281,018 ) - Accumulated deficit (281,544 ) (3,390,115 ) (3,671,659 ) Total shareholders’ equity (deficit) 5,000,006 (8,671,220 ) (3,671,214 ) Total liabilities, ordinary shares subject to possible redemption and shareholders’ equity (deficit) $ 162,103,252 $ - $ 162,103,252 Number of Public Shares subject to redemption 15,132,878 867,122 16,000,000 Number of Ordinary Shares non-redeemable 5,317,122 (867,122 ) 4,450,000 The Company’s unaudited condensed statement of shareholders’ equity (deficit) has been restated to reflect the changes to the impacted shareholders’ equity (deficit) accounts described above. For the Three Months Ended March 31, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Operations Net loss $ (108,002 ) $ - $ (108,002 ) Weighted average shares outstanding of Public Shares, basic and diluted 16,000,000 (16,000,000 ) - Basic and diluted net loss per Public Share $ - $ - $ - Weighted average shares outstanding of Founder Shares, basic and diluted 4,450,000 (4,450,000 ) - Basic and diluted net loss per Founder Share $ (0.03 ) $ 0.03 $ - Weighted average shares outstanding of ordinary shares, basic and diluted - 20,450,000 20,450,000 Basic and diluted net loss per ordinary share $ - $ (0.01 ) $ (0.01 ) For the Three Months Ended March 31, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Cash Flows - Supplemental disclosure of noncash activities: Change in fair value of ordinary shares subject to possible redemption $ (107,999 ) $ 107,999 $ - The tables below present the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported unaudited condensed balance sheet as of June 30, 2021, statements of operations for the three and six months ended June 30, 2021, and statement of cash flows for the six months ended June 30, 2021: As of June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Balance Sheet Total Assets $ 162,031,351 $ - $ 162,031,351 Total liabilities $ 5,794,894 $ - $ 5,794,894 Ordinary shares subject to possible redemption 151,236,450 8,763,550 160,000,000 Shareholders’ equity (deficit) Preference shares - - - Ordinary shares 533 (88 ) 445 Additional paid-in-capital 5,373,347 (5,373,347 ) - Accumulated deficit (373,873 ) (3,390,115 ) (3,763,988 ) Total shareholders’ equity (deficit) 5,000,007 (8,763,550 ) (3,763,543 ) Total liabilities, ordinary shares subject to possible redemption and shareholders’ equity (deficit) $ 162,031,351 $ - $ 162,031,351 Number of Public Shares subject to redemption 15,123,645 876,355 16,000,000 Number of Ordinary Shares non-redeemable 5,326,355 (876,355 ) 4,450,000 The Company’s unaudited condensed statement of shareholders’ equity (deficit) has been restated to reflect the changes to the impacted shareholders’ equity (deficit) accounts described above. For the Three Months Ended June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Operations Net loss $ (92,329 ) $ - $ (92,329 ) Weighted average shares outstanding of Public Shares, basic and diluted 16,000,000 (16,000,000 ) - Basic and diluted net loss per Public Share $ - $ - $ - Weighted average shares outstanding of Founder Shares, basic and diluted 4,450,000 (4,450,000 ) - Basic and diluted net loss per Founder Share $ (0.02 ) $ 0.02 $ - Weighted average shares outstanding of ordinary shares, basic and diluted - 20,450,000 20,450,000 Basic and diluted net loss per ordinary share $ - $ - $ (0.00 ) For the Six Months Ended June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Operations Net loss $ (200,331 ) $ - $ (200,331 ) Weighted average shares outstanding of Public Shares, basic and diluted 16,000,000 (16,000,000 ) - Basic and diluted net loss per Public Share $ - $ - $ - Weighted average shares outstanding of Founder Shares, basic and diluted 4,450,000 (4,450,000 ) - Basic and diluted net loss per Founder Share $ 0.05 $ (0.05 ) $ - Weighted average shares outstanding of ordinary shares, basic and diluted - 20,450,000 20,450,000 Basic and diluted net loss per ordinary share $ - $ (0.01 ) $ (0.01 ) For the Six Months Ended June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Cash Flows - Supplemental disclosure of noncash activities: Change in fair value of ordinary shares subject to possible redemption $ (200,330 ) $ 200,330 $ -

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Account Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Account Policies	Note 3 - Basis of Presentation and Summary of Significant Account Policies Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected through December 31, 2021. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 10, 2021. Emerging Growth Company As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at September 30, 2021 and December 31, 2020. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. The Company’s investments held in the Trust Account as of September 30, 2021, and December 31, 2020, are comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in a money market funds that comprise only U.S. Treasury securities money market funds. Investments Held in the Trust Account The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in net gain from investments held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements,” approximate the carrying amounts represented in the condensed balance sheets. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: ● Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; ● Level 2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly; ● Level 3: Prices or valuations that require significant unobservable inputs (including the Management’s assumptions in determining fair value measurement). In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Offering Costs Associated with Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - “Expenses of Offering.” Offering costs consist of costs incurred in connection with the formation and preparation for the Initial Public Offering. These costs, together with the underwriting discount, were charged to the carrying value of the Public Shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. Ordinary Shares Subject to Possible Redemption Ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events, Accordingly, at September 30, 2021 and December 31, 2020, 16,000,000 of its ordinary shares subject to possible redemption at the redemption amount were presented at redemption value as temporary equity, respectively, outside of the shareholders’ equity (deficit) section of the Company’s condensed balance sheets. Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit. Net Loss per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average number of ordinary shares outstanding for the respective period. The calculation of diluted net income (loss) per ordinary share does not consider the effect of the warrants underlying the Units sold in the Private Placement Warrants to purchase 1,500,000 ordinary shares since their exercise is contingent upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net loss per share is the same as basic net loss per share for the three and nine months ended September 30, 2021. Accretion associated with the redeemable ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Income Taxes ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying unaudited condensed financial statements.

Initial Public Offering

Initial Public Offering	9 Months Ended
	Sep. 30, 2021
Proposed Public Offering [Abstract]
Initial Public Offering	Note 4 - Initial Public Offering On August 6, 2020, the Company consummated its Initial Public Offering of 16,000,000 Public Shares, including the 2,086,956 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $160.0 million, and incurring offering costs of approximately $9.4 million, inclusive of approximately $5.6 million in deferred underwriting commissions.

Private Placement

Private Placement	9 Months Ended
	Sep. 30, 2021
Private Placement Disclosure [Abstract]
Private Placement	Note 5 - Private Placement Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of (i) 450,000 Private Placement Share at $10.00 per Private Placement Share (for a total purchase price of $4.5 million) and (ii) 1,500,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), for an aggregate of $6.0 million from the Sponsor, generating gross proceeds to the Company of $6.0 million. Each Private Placement Warrant entitles the holder thereof to purchase one ordinary share at an exercise price of $11.50 per ordinary share. A portion of the proceeds from the Private Placement Warrants and the Private Placement Shares were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 - Related Party Transactions Insider Shares On June 11, 2020, the Company issued 3,593,750 ordinary shares to the Sponsor (the “Insider Shares”) for an aggregate purchase price of $28,750. On August 3, 2020, the Company effected a share dividend of 0.113043478 ordinary shares for each outstanding ordinary share (an aggregate of 406,250 ordinary shares), resulting in an aggregate of 4,000,000 ordinary shares outstanding. The holders of the Insider Shares had agreed to forfeit up to an aggregate of 521,739 Insider Shares, on a pro rata basis, to the extent that the option to purchase additional ordinary shares was not exercised in full by the underwriters. The forfeiture would have been adjusted to the extent that the option to purchase additional ordinary shares is not exercised in full by the underwriters so that the Insider Shares will represent 20% of the Company’s issued and outstanding shares after the Initial Public Offering (excluding the Private Placement Shares and assuming the initial shareholders do not purchase any Public Shares in the Initial Public Offering). On August 6, 2020, the underwriters fully exercised the over-allotment option; thus, the 521,739 Insider Shares were no longer subject to forfeiture. The Initial Shareholders agreed not to transfer, assign or sell any of their Insider Shares (except to certain permitted transferees) until, with respect to 50% of the Insider Shares, the earlier of six months after the date of the consummation of the initial Business Combination and the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per ordinary share for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination, and, with respect to the remaining 50% of the Insider Shares, six months after the date of the consummation of the initial Business Combination, or earlier in each case if, subsequent to the initial Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property. Related Party Loans On June 11, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note was non-interest bearing, unsecured and due on the date the Company consummates the Initial Public Offering or the date on which the Company determines not to conduct the Initial Public Offering. The Company borrowed $300,000 under the Note, and fully repaid the Note in full on August 7, 2020. The Note is no longer available to the Company to draw on. In addition, in order to finance transaction costs in connection with a Business Combination, the Initial Shareholders may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion (the “Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the Business Combination into additional private warrants at a price of $1.00 per warrant. If the Company does not complete a Business Combination within the Combination Period, the Working Capital Loans will be repaid only from amounts remaining outside the Trust Account, if any. The warrants would be identical to the Private Placement Warrants. As of September 30, 2021, and December 31, 2020, the Company had no borrowings under the Working Capital Loans. Administrative support agreement Commencing on the date of the Company’s prospectus, the Company agreed to pay an affiliate of the Sponsor a total of $10,000 per month for office space and certain office and secretarial services. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. During the three and the nine months ended September 30, 2021, the Company incurred $30,000 and $90,000 in expenses for these services which is recognized in the accompanying unaudited condensed statement of operations, respectively. As of September 30, 2021, and December 31, 2020, there were $120,000 and $30,000 in accrued expenses - related party outstanding, as reflected in the accompanying condensed balance sheets. Purchase Agreement The Sponsor has entered into an agreement with the Company to purchase an aggregate of 2,500,000 of the Company’s ordinary shares or their equivalent in the securities of a target company for an aggregate purchase price of $25,000,000 prior to, concurrently with, or following the closing of the Business Combination, either in open market transactions (to the extent permitted by law) or in a private placement. The capital from such transaction may be used as part of the consideration to the sellers in the initial Business Combination, and any excess capital fund from such private placement would be used for working capital in the post-transaction company.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 - Commitments and Contingencies Registration and Shareholder Rights The holders of the Insider Shares, Private Placement Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the Insider Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the Private Placement Shares, Private Placement Warrants or ordinary shares issued in payment of Working Capital Loans made to the Company can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the date of this prospectus to purchase up to 2,086,956 additional Ordinary Shares at the Initial Public Offering price less the underwriting discounts and commissions. On August 6, 2020, the underwriters fully exercised the over-allotment option. The underwriters were entitled to an underwriting discount of $0.20 per Public Share, or $3.2 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, the underwriters were entitled to a deferred underwriting commission of $0.35 per Public Share, or $5.6 million in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Ordinary Shares Subject to Poss

Ordinary Shares Subject to Possible Redemption	9 Months Ended
	Sep. 30, 2021
Ordinary Shares Subject To Possible Redemption Disclosure [Abstract]
Ordinary Shares Subject to Possible Redemption	Note 8 - Ordinary Shares Subject to Possible Redemption The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 100,000,000 ordinary shares with a par value of $0.0001 per share. Holders of the Company’s ordinary shares are entitled to one vote for each share. As of September 30, 2021, there were 20,450,000 ordinary shares outstanding, 16,000,000 of which were subject to possible redemption and are classified outside of permanent equity in the condensed balance sheets. The ordinary shares subject to possible redemption reflected on the condensed balance sheets is reconciled on the following table: Gross proceeds received from Initial Public Offering $ 160,000,000 Less: Offering costs allocated to Public Shares (9,418,420 ) Plus: Accretion on ordinary shares to redemption value 9,418,420 Ordinary shares subject to possible redemption $ 160,000,000

Shareholders_ Deficit

Shareholders’ Deficit	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Shareholders’ Deficit	Note 9 - Shareholders’ Deficit Preference shares Ordinary Shares Private Warrants Each warrant is exercisable to purchase one of ordinary shares at an exercise price of $11.50 per full share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share capitalization, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants shares. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10 - Fair Value Measurements The following tables present information about the Company’s financial assets that are measured at fair value on a recurring basis by level within the fair value hierarchy: September 30, 2021 Description Quoted Prices Significant Significant Investments held in Trust Account $ 160,018,413 $ - $ - December 31, 2020 Description Quoted Prices Significant Significant Investments held in Trust Account $ 160,006,444 $ - $ - Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and the nine months ended September 30, 2021. Level 1 assets include investments in mutual funds that invest solely in U.S. government securities. The Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 11 - Subsequent Events The Company evaluated subsequent events and transactions that occurred through the date that the unaudited condensed financial statements were issued. The Company did not identify any subsequent events, other than the restatement discussed in Note 2, that would have required adjustment or disclosure in the unaudited condensed financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected through December 31, 2021. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 10, 2021.
Emerging Growth Company	Emerging Growth Company As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of estimates	Use of Estimates The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at September 30, 2021 and December 31, 2020.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. The Company’s investments held in the Trust Account as of September 30, 2021, and December 31, 2020, are comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in a money market funds that comprise only U.S. Treasury securities money market funds.
Investments Held in the Trust Account	Investments Held in the Trust Account The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in net gain from investments held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements,” approximate the carrying amounts represented in the condensed balance sheets.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: ● Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; ● Level 2: Quoted prices in markets that are not active or financial instruments for which significant inputs to models are observable (including but not limited to quoted prices for similar securities, interest rates, foreign exchange rates, volatility and credit risk), either directly or indirectly; ● Level 3: Prices or valuations that require significant unobservable inputs (including the Management’s assumptions in determining fair value measurement). In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Offering Costs Associated with Initial Public Offering	Offering Costs Associated with Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - “Expenses of Offering.” Offering costs consist of costs incurred in connection with the formation and preparation for the Initial Public Offering. These costs, together with the underwriting discount, were charged to the carrying value of the Public Shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.
Ordinary Shares Subject to Possible Redemption	Ordinary Shares Subject to Possible Redemption Ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events, Accordingly, at September 30, 2021 and December 31, 2020, 16,000,000 of its ordinary shares subject to possible redemption at the redemption amount were presented at redemption value as temporary equity, respectively, outside of the shareholders’ equity (deficit) section of the Company’s condensed balance sheets. Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.
Net Loss per Ordinary Share	Net Loss per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income (loss) per ordinary share is calculated by dividing the net income (loss) by the weighted average number of ordinary shares outstanding for the respective period. The calculation of diluted net income (loss) per ordinary share does not consider the effect of the warrants underlying the Units sold in the Private Placement Warrants to purchase 1,500,000 ordinary shares since their exercise is contingent upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net loss per share is the same as basic net loss per share for the three and nine months ended September 30, 2021. Accretion associated with the redeemable ordinary shares is excluded from earnings per share as the redemption value approximates fair value.
Income Taxes	Income Taxes ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statement. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying unaudited condensed financial statements.

Restatement of Previously Rep_2

Restatement of Previously Reported Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2021
Restatement Of Previously Reported Financial Statements [Abstract]
Schedule of unaudited condensed balance sheet	As of March 31, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Balance Sheet Total Assets $ 162,103,252 $ - $ 162,103,252 Total liabilities $ 5,774,466 $ - $ 5,774,466 Ordinary shares subject to possible redemption 151,328,780 8,671,220 160,000,000 Shareholders’ equity (deficit) Preference shares - - - Ordinary shares 532 (87 ) 445 Additional paid-in-capital 5,281,018 (5,281,018 ) - Accumulated deficit (281,544 ) (3,390,115 ) (3,671,659 ) Total shareholders’ equity (deficit) 5,000,006 (8,671,220 ) (3,671,214 ) Total liabilities, ordinary shares subject to possible redemption and shareholders’ equity (deficit) $ 162,103,252 $ - $ 162,103,252 Number of Public Shares subject to redemption 15,132,878 867,122 16,000,000 Number of Ordinary Shares non-redeemable 5,317,122 (867,122 ) 4,450,000 As of June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Balance Sheet Total Assets $ 162,031,351 $ - $ 162,031,351 Total liabilities $ 5,794,894 $ - $ 5,794,894 Ordinary shares subject to possible redemption 151,236,450 8,763,550 160,000,000 Shareholders’ equity (deficit) Preference shares - - - Ordinary shares 533 (88 ) 445 Additional paid-in-capital 5,373,347 (5,373,347 ) - Accumulated deficit (373,873 ) (3,390,115 ) (3,763,988 ) Total shareholders’ equity (deficit) 5,000,007 (8,763,550 ) (3,763,543 ) Total liabilities, ordinary shares subject to possible redemption and shareholders’ equity (deficit) $ 162,031,351 $ - $ 162,031,351 Number of Public Shares subject to redemption 15,123,645 876,355 16,000,000 Number of Ordinary Shares non-redeemable 5,326,355 (876,355 ) 4,450,000
Schedule of unaudited condensed statement of operations	For the Three Months Ended March 31, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Operations Net loss $ (108,002 ) $ - $ (108,002 ) Weighted average shares outstanding of Public Shares, basic and diluted 16,000,000 (16,000,000 ) - Basic and diluted net loss per Public Share $ - $ - $ - Weighted average shares outstanding of Founder Shares, basic and diluted 4,450,000 (4,450,000 ) - Basic and diluted net loss per Founder Share $ (0.03 ) $ 0.03 $ - Weighted average shares outstanding of ordinary shares, basic and diluted - 20,450,000 20,450,000 Basic and diluted net loss per ordinary share $ - $ (0.01 ) $ (0.01 ) For the Three Months Ended June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Operations Net loss $ (92,329 ) $ - $ (92,329 ) Weighted average shares outstanding of Public Shares, basic and diluted 16,000,000 (16,000,000 ) - Basic and diluted net loss per Public Share $ - $ - $ - Weighted average shares outstanding of Founder Shares, basic and diluted 4,450,000 (4,450,000 ) - Basic and diluted net loss per Founder Share $ (0.02 ) $ 0.02 $ - Weighted average shares outstanding of ordinary shares, basic and diluted - 20,450,000 20,450,000 Basic and diluted net loss per ordinary share $ - $ - $ (0.00 ) For the Six Months Ended June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Operations Net loss $ (200,331 ) $ - $ (200,331 ) Weighted average shares outstanding of Public Shares, basic and diluted 16,000,000 (16,000,000 ) - Basic and diluted net loss per Public Share $ - $ - $ - Weighted average shares outstanding of Founder Shares, basic and diluted 4,450,000 (4,450,000 ) - Basic and diluted net loss per Founder Share $ 0.05 $ (0.05 ) $ - Weighted average shares outstanding of ordinary shares, basic and diluted - 20,450,000 20,450,000 Basic and diluted net loss per ordinary share $ - $ (0.01 ) $ (0.01 )
Schedule of unaudited condensed statement of cash flows	For the Three Months Ended March 31, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Cash Flows - Supplemental disclosure of noncash activities: Change in fair value of ordinary shares subject to possible redemption $ (107,999 ) $ 107,999 $ - For the Six Months Ended June 30, 2021 As Previously Reported Adjustment As Restated Unaudited Condensed Statement of Cash Flows - Supplemental disclosure of noncash activities: Change in fair value of ordinary shares subject to possible redemption $ (200,330 ) $ 200,330 $ -

Ordinary Shares Subject to Po_2

Ordinary Shares Subject to Possible Redemption (Tables)	9 Months Ended
	Sep. 30, 2021
Ordinary Shares Subject To Possible Redemption Disclosure [Abstract]
Schedule of condensed balance sheets is reconciled	Gross proceeds received from Initial Public Offering $ 160,000,000 Less: Offering costs allocated to Public Shares (9,418,420 ) Plus: Accretion on ordinary shares to redemption value 9,418,420 Ordinary shares subject to possible redemption $ 160,000,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of financial assets that are measured at fair value on a recurring basis	Description Quoted Prices Significant Significant Investments held in Trust Account $ 160,018,413 $ - $ - Description Quoted Prices Significant Significant Investments held in Trust Account $ 160,006,444 $ - $ -

Description of Organization a_2

Description of Organization and Business Operations (Details) - USD ($)	Aug. 06, 2020	Sep. 30, 2021
Description of Organization and Business Operations (Details) [Line Items]
Price per share (in Dollars per share)		$ 10
Gross proceeds (in Shares)	160,000,000
Description of private placement warrant		Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share to the Sponsor, (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (“Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (Note 5).
Assets held in the trust account, percentage		80.00%
Price per unit (in Dollars per share)	$ 10
Public share per share value (in Shares)		10
Net tangible assets		$ 5,000,001
Aggregate shares, percentage		20.00%
Redeem shares, percentage		100.00%
Cash		$ 1,800,000
Working capital		1,700,000
Sponsor [Member]
Description of Organization and Business Operations (Details) [Line Items]
Capital contribution		28,750
Loan amount		$ 300,000
Business Combination [Member]
Description of Organization and Business Operations (Details) [Line Items]
Outstanding voting security percentage		50.00%
Description of business combination		Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing.
Initial Public Offering [Member]
Description of Organization and Business Operations (Details) [Line Items]
Issuance of initial public offering units (in Shares)	16,000,000
Issuance of public shares under over-allotment (in Shares)	2,086,956
Price per share (in Dollars per share)	$ 10
Offering cost	$ 9,400,000
Deferred underwriting commission	$ 5,600,000
Private Placement [Member]
Description of Organization and Business Operations (Details) [Line Items]
Price per share (in Dollars per share)		$ 10
Private placement, amount		$ 160,000,000
Public Shareholders [Member]
Description of Organization and Business Operations (Details) [Line Items]
Price per unit (in Dollars per share)		$ 10

Restatement of Previously Rep_3

Restatement of Previously Reported Financial Statements (Details)	Sep. 30, 2021USD ($)
Restatement Of Previously Reported Financial Statements [Abstract]
Net tangible assets	$ 5,000,001

Restatement of Previously Rep_4

Restatement of Previously Reported Financial Statements (Details) - Schedule of unaudited condensed balance sheet - USD ($)	Jun. 30, 2021	Mar. 31, 2021
As Previously Reported [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Total Assets	$ 162,031,351	$ 162,103,252
Total liabilities	5,794,894	5,774,466
Ordinary shares subject to possible redemption	151,236,450	151,328,780
Shareholders’ equity (deficit)
Preference shares
Ordinary shares (in Shares)	533	532
Additional paid-in-capital	$ 5,373,347	$ 5,281,018
Accumulated deficit	(373,873)	(281,544)
Total shareholders’ equity (deficit)	5,000,007	5,000,006
Total liabilities, ordinary shares subject to possible redemption and shareholders’ equity (deficit)	$ 162,031,351	$ 162,103,252
Number of Public Shares subject to redemption (in Shares)	15,123,645	15,132,878
Number of Ordinary Shares non-redeemable (in Shares)	5,326,355	5,317,122
Adjustment [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Total Assets
Total liabilities
Ordinary shares subject to possible redemption	8,763,550	8,671,220
Shareholders’ equity (deficit)
Preference shares
Ordinary shares (in Shares)	(88)	(87)
Additional paid-in-capital	$ (5,373,347)	$ (5,281,018)
Accumulated deficit	(3,390,115)	(3,390,115)
Total shareholders’ equity (deficit)	(8,763,550)	(8,671,220)
Total liabilities, ordinary shares subject to possible redemption and shareholders’ equity (deficit)
Number of Public Shares subject to redemption (in Shares)	876,355	867,122
Number of Ordinary Shares non-redeemable (in Shares)	(876,355)	(867,122)
As Restated [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Total Assets	$ 162,031,351	$ 162,103,252
Total liabilities	5,794,894	5,774,466
Ordinary shares subject to possible redemption	160,000,000	160,000,000
Shareholders’ equity (deficit)
Preference shares
Ordinary shares (in Shares)	445	445
Additional paid-in-capital
Accumulated deficit	(3,763,988)	(3,671,659)
Total shareholders’ equity (deficit)	(3,763,543)	(3,671,214)
Total liabilities, ordinary shares subject to possible redemption and shareholders’ equity (deficit)	$ 162,031,351	$ 162,103,252
Number of Public Shares subject to redemption (in Shares)	16,000,000	16,000,000
Number of Ordinary Shares non-redeemable (in Shares)	4,450,000	4,450,000

Restatement of Previously Rep_5

Restatement of Previously Reported Financial Statements (Details) - Schedule of unaudited condensed statement of operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021
As Previously Reported [Member]
Condensed Income Statements, Captions [Line Items]
Net loss	$ (92,329)	$ (108,002)	$ (200,331)
Weighted average shares outstanding of Public Shares, basic and diluted	16,000,000	16,000,000	16,000,000
Basic and diluted net loss per Public Share
Weighted average shares outstanding of Founder Shares, basic and diluted	4,450,000	4,450,000	4,450,000
Basic and diluted net loss per Founder Share	$ (0.02)	$ (0.03)	$ 0.05
Weighted average shares outstanding of ordinary shares, basic and diluted
Basic and diluted net loss per ordinary share
Adjustment [Member]
Condensed Income Statements, Captions [Line Items]
Net loss
Weighted average shares outstanding of Public Shares, basic and diluted	(16,000,000)	(16,000,000)	(16,000,000)
Basic and diluted net loss per Public Share
Weighted average shares outstanding of Founder Shares, basic and diluted	(4,450,000)	(4,450,000)	(4,450,000)
Basic and diluted net loss per Founder Share	$ 0.02	$ 0.03	$ (0.05)
Weighted average shares outstanding of ordinary shares, basic and diluted	20,450,000	20,450,000	20,450,000
Basic and diluted net loss per ordinary share		$ (0.01)	$ (0.01)
As Restated [Member]
Condensed Income Statements, Captions [Line Items]
Net loss	$ (92,329)	$ (108,002)	$ (200,331)
Weighted average shares outstanding of Public Shares, basic and diluted
Basic and diluted net loss per Public Share
Weighted average shares outstanding of Founder Shares, basic and diluted
Basic and diluted net loss per Founder Share
Weighted average shares outstanding of ordinary shares, basic and diluted	20,450,000	20,450,000	20,450,000
Basic and diluted net loss per ordinary share	$ 0	$ (0.01)	$ (0.01)

Restatement of Previously Rep_6

Restatement of Previously Reported Financial Statements (Details) - Schedule of unaudited condensed statement of cash flows - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Jun. 30, 2021
As Previously Reported [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Change in fair value of ordinary shares subject to possible redemption	$ (107,999)	$ (200,330)
Adjustment [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Change in fair value of ordinary shares subject to possible redemption	107,999	200,330
As Restated [Member]
Condensed Cash Flow Statements, Captions [Line Items]
Change in fair value of ordinary shares subject to possible redemption

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Account Policies (Details)	9 Months Ended
	Sep. 30, 2021USD ($)shares
Accounting Policies [Abstract]
Federal depository insurance coverage amount (in Dollars) | $	$ 250,000
Shares subject to possible redemption	16,000,000
Warrants to purchase ordinary shares	1,500,000

Initial Public Offering (Detail

Initial Public Offering (Details) $ / shares in Units, $ in Millions	Aug. 06, 2020USD ($)$ / sharesshares
Initial Public Offering (Details) [Line Items]
Price per share (in Dollars per share) | $ / shares	$ 10
Gross proceeds	$ 160
Offering costs	9.4
Deferred underwriting commissions	$ 5.6
Initial Public Offering [Member]
Initial Public Offering (Details) [Line Items]
Shares issued (in Shares) | shares	16,000,000
Over-Allotment Option [Member]
Initial Public Offering (Details) [Line Items]
Shares issued (in Shares) | shares	2,086,956

Private Placement (Details)

Private Placement (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Private Placement (Details) [Line Items]
Sale of stock price per share (in Dollars per share) | $ / shares	$ 10
Price per unit (in Dollars per share) | $ / shares	$ 11.5
Aggregate amount of private placement | $	$ 6
Generating gross proceeds | $	$ 6
Private Placement [Member]
Private Placement (Details) [Line Items]
Purchase of shares (in Shares) | shares	450,000
Sale of stock price per share (in Dollars per share) | $ / shares	$ 10
Purchase price | $	$ 4.5
Private placement warrants, shares (in Shares) | shares	1,500,000
Price per unit (in Dollars per share) | $ / shares	$ 1
Aggregate Price Paid | $	$ 1.5

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Aug. 07, 2020	Aug. 06, 2020	Jun. 11, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2021	Aug. 03, 2020
Related Party Transactions (Details) [Line Items]
Ordinary share, issued (in Shares)				4,450,000	4,450,000	4,450,000
Ordinary stock, shares outstanding (in Shares)				4,450,000	4,450,000	4,450,000
Issued and outstanding shares, percentage						20.00%
Related party, description						The Initial Shareholders agreed not to transfer, assign or sell any of their Insider Shares (except to certain permitted transferees) until, with respect to 50% of the Insider Shares, the earlier of six months after the date of the consummation of the initial Business Combination and the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per ordinary share for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination, and, with respect to the remaining 50% of the Insider Shares, six months after the date of the consummation of the initial Business Combination, or earlier in each case if, subsequent to the initial Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.
Payments of loan costs			$ 300,000
Borrowed amount	$ 300,000
Warrants conversion, description						The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the Business Combination into additional private warrants at a price of $1.00 per warrant.
Incurred expenses				$ 30,000		$ 90,000
Accrued expenses related party outstanding					$ 30,000	$ 120,000
Aggregate purchase to ordinary shares (in Shares)						2,500,000
Aggregate to purchase price						$ 25,000,000
Sponsor [Member]
Related Party Transactions (Details) [Line Items]
Ordinary share, issued (in Shares)			3,593,750
Aggregate price			$ 28,750
Sponsor forfeit shares (in Shares)						521,739
Administrative expenses						$ 10,000
Ordinary Shares [Member]
Related Party Transactions (Details) [Line Items]
Ordinary share, issued (in Shares)			3,593,750
Dividend per share value (in Dollars per share)							$ 0.113043478
Shares outstanding (in Shares)							406,250
Ordinary stock, shares outstanding (in Shares)				20,450,000	16,000,000	20,450,000	4,000,000
Insider Shares [Member]
Related Party Transactions (Details) [Line Items]
Subject to forfeiture, shares (in Shares)		521,739

Commitments and Contingencies (

Commitments and Contingencies (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)$ / shares
Commitments and Contingencies (Details) [Line Items]
Underwriting agreement, description	The Company granted the underwriters a 45-day option from the date of this prospectus to purchase up to 2,086,956 additional Ordinary Shares at the Initial Public Offering price less the underwriting discounts and commissions.
Underwriting discount rate | $ / shares	$ 0.2
Underwriting discount fee deferred | $ / shares	$ 0.35
Over-Allotment Option [Member]
Commitments and Contingencies (Details) [Line Items]
Underwriting expense | $	$ 3.2
Deferred underwriting commission | $	$ 5.6

Ordinary Shares Subject to Po_3

Ordinary Shares Subject to Possible Redemption (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Ordinary Shares Subject To Possible Redemption Disclosure [Abstract]
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Voting, rights	Holders of the Company’s ordinary shares are entitled to one vote for each share.
Ordinary shares outstanding	20,450,000
Shares subject to possible redemption	16,000,000

Ordinary Shares Subject to Po_4

Ordinary Shares Subject to Possible Redemption (Details) - Schedule of condensed balance sheets is reconciled	9 Months Ended
	Sep. 30, 2021USD ($)
Schedule of condensed balance sheets is reconciled [Abstract]
Gross proceeds received from Initial Public Offering	$ 160,000,000
Less:
Offering costs allocated to Public Shares	(9,418,420)
Plus:
Accretion on ordinary shares to redemption value	9,418,420
Ordinary shares subject to possible redemption	$ 160,000,000

Shareholders_ Deficit (Details)

Shareholders’ Deficit (Details) - $ / shares	Aug. 06, 2020	Aug. 03, 2020	Sep. 30, 2021	Dec. 31, 2020	Jun. 11, 2020
Shareholders’ Deficit (Details) [Line Items]
Preferred stock, shares authorized			1,000,000	1,000,000
Preferred stock, par value, (in Dollars per share)			$ 0.0001	$ 0.0001
Ordinary shares, authorized			100,000,000	100,000,000
Ordinary shares, par value (in Dollars per share)			$ 0.0001	$ 0.0001
Ordinary shares, issued			4,450,000	4,450,000
Stockholders equity, description		the Company effected a share dividend of 0.113043478 ordinary shares for each outstanding share (an aggregate of 406,250 ordinary shares), resulting in an aggregate of 4,000,000 ordinary shares outstanding. All ordinary shares and associated amounts have been retroactively restated to reflect the share dividend. Of the 4,000,000 ordinary shares outstanding, up to 521,739 of these ordinary shares was subject to forfeiture by the Sponsor (or its permitted transferees) on a pro rata basis depending on the extent to which the underwriters’ over-allotment option was exercised.
Ordinary, shares outstanding			4,450,000	4,450,000
Issuance of public offering	160,000,000
Warrants, description			Each warrant is exercisable to purchase one of ordinary shares at an exercise price of $11.50 per full share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.
Ordinary Shares [Member]
Shareholders’ Deficit (Details) [Line Items]
Ordinary shares, issued					3,593,750
Shares, outstanding		406,250
Ordinary, shares outstanding		4,000,000	20,450,000	16,000,000
Over-Allotment Option [Member]
Shareholders’ Deficit (Details) [Line Items]
Issuance of public offering	521,739

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]
Investments held in Trust Account	$ 160,018,413	$ 160,006,444
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]
Investments held in Trust Account
Significant Other Unobservable Inputs (Level 3) [Member]
Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]
Investments held in Trust Account